Le Lézard
Classified in: Health
Subjects: EXE, PSF

/R E P E A T -- Advisory - Alesse 21 and 28 birth control pill: Packages may contain broken or smaller-than-normal pills, which may reduce effectiveness in preventing pregnancy/


OTTAWA, Dec. 1, 2017 /CNW/ -

Issue
Health Canada is advising consumers and health care professionals that complaints have been received for packages of Alesse 21 (21 active pills) and Alesse 28 (21 active pills, 7 that contain no hormones). The blister packages for both contained an active (pink) pill that was roughly half the proper size. 

Alesse 21 and Alesse 28 are prescription drugs used to prevent pregnancy.

Who is affected

Affected products

What consumers should do

Additional information for pharmacists:

Background
Broken or smaller-than-normal birth control pills may deliver a smaller dose of the active drug ingredient, which could reduce its effectiveness in preventing pregnancy.

What Health Canada is doing
Health Canada is working with the company, Pfizer Canada, to determine the nature and scope of the issue. We will continue to monitor the situation and assess the need for further action. Health Canada will update consumers and health care professionals as appropriate.

For more information
Stay connected with Health Canada and receive the latest advisories and product recalls using social media tools.

Également disponible en français

 

SOURCE Health Canada


These press releases may also interest you

26 avr 2024
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

26 avr 2024
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

26 avr 2024
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

26 avr 2024
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

26 avr 2024
David J. Dykeman, co-chair of the Life Sciences & Medical...

26 avr 2024
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...



News published on and distributed by: